Clinical management of Von Hippel-Lindau (VHL) disease
- PMID: 11705642
- DOI: 10.1016/s0300-2977(01)00165-6
Clinical management of Von Hippel-Lindau (VHL) disease
Abstract
Von Hippel-Lindau (VHL) disease is an autosomal, dominant inherited tumour syndrome with an estimated prevalence of 2-3 per 100,000 persons. A germline mutation in the VHL gene predisposes carriers to tumours in multiple organs. These tumours may include haemangioblastoma in the retina and central nervous system (CNS), renal cell carcinoma, phaeochromocytoma, islet cell tumours of the pancreas, and endolymphatic sac tumours, as well as cysts and cystadenoma in the kidney, pancreas, epididymis and broad ligament. Penetrance of VHL disease is high, most carriers of a VHL germline mutation develop one or more tumours by the age of 60 years. The most common symptoms include: loss of vision, raised intracranial pressure, neurological deficits, paroxysmal raised blood pressure and local pain. At present, metastases from renal cell carcinoma and neurological complications from cerebellar haemangioblastoma are the most common causes of death. However, it is anticipated that intensive radiological and clinical monitoring, and advanced operation techniques will reduce both morbidity and mortality in patients with VHL disease.
Similar articles
-
The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system.J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):758-62. doi: 10.1136/jnnp.67.6.758. J Neurol Neurosurg Psychiatry. 1999. PMID: 10567493 Free PMC article.
-
[Hippel-Lindau disease].Neurol Neurochir Pol. 1998 Sep-Oct;32(5):1119-33. Neurol Neurochir Pol. 1998. PMID: 10463227 Review. Polish.
-
From arterial hypertension complications to von Hippel-Lindau syndrome diagnosis.Ital J Pediatr. 2015 Aug 13;41:56. doi: 10.1186/s13052-015-0158-y. Ital J Pediatr. 2015. PMID: 26268347 Free PMC article.
-
Investigation and Management of Apparently Sporadic Central Nervous System Haemangioblastoma for Evidence of Von Hippel-Lindau Disease.Genes (Basel). 2021 Sep 15;12(9):1414. doi: 10.3390/genes12091414. Genes (Basel). 2021. PMID: 34573396 Free PMC article.
-
[Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].Ann Endocrinol (Paris). 1998;59(6):452-8. Ann Endocrinol (Paris). 1998. PMID: 10189987 Review. French.
Cited by
-
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.Oncogene. 2005 Feb 3;24(6):1043-52. doi: 10.1038/sj.onc.1208305. Oncogene. 2005. PMID: 15592504 Free PMC article.
-
Intra-Familial Phenotypic Heterogeneity and Telomere Abnormality in von Hippel- Lindau Disease: Implications for Personalized Surveillance Plan and Pathogenesis of VHL-Associated Tumors.Front Genet. 2019 Apr 24;10:358. doi: 10.3389/fgene.2019.00358. eCollection 2019. Front Genet. 2019. PMID: 31068970 Free PMC article.
-
Multidisciplinary integrated care pathway for von Hippel-Lindau disease.Cancer. 2022 Aug 1;128(15):2871-2879. doi: 10.1002/cncr.34265. Epub 2022 May 17. Cancer. 2022. PMID: 35579632 Free PMC article.
-
Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report.Target Oncol. 2012 Jun;7(2):145-9. doi: 10.1007/s11523-012-0214-0. Epub 2012 Feb 29. Target Oncol. 2012. PMID: 22374327 Free PMC article.
-
Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.Mol Cell Biol. 2005 Apr;25(8):3163-72. doi: 10.1128/MCB.25.8.3163-3172.2005. Mol Cell Biol. 2005. PMID: 15798202 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical